NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Top Cited Papers
Open Access
- 1 March 2020
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 18 (3), 230-241
- https://doi.org/10.6004/jnccn.2020.0012
Abstract
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs. The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.Keywords
This publication has 64 references indexed in Scilit:
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocrine-Related Cancer, 2014
- Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill PatientAnnals of Pharmacotherapy, 2014
- Mitigating the toxic effects of anticancer immunotherapyNature Reviews Clinical Oncology, 2014
- Real-world impact of education: treating patients with ipilimumab in a community practice settingCancer Management and Research, 2013
- Ipilimumab-induced acute severe colitis treated by infliximabMelanoma Research, 2013
- Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Report from a consensus conference on antibody-mediated rejection in heart transplantationThe Journal of Heart and Lung Transplantation, 2011
- Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year ReportAmerican Journal of Transplantation, 2006
- Antibody‐Mediated Rejection in Human Cardiac Allografts: Evaluation of Immunoglobulins and Complement Activation Products C4d and C3d as MarkersAmerican Journal of Transplantation, 2005